新闻源 财富源

2019年10月18日 星期五

康缘药业(600557)公告正文

康缘药业:2015年第三季度报告

公告日期:2015-10-30

   江苏康缘药业股份有限公司 (股票代码:600557)               2015 年第三季度报告



公司代码:600557                                            公司简称:康缘药业




                  江苏康缘药业股份有限公司
                      公司代码:600557

                         2015 年第三季度报告




                              二〇一五 年 十 月 二十九 日



                                             1 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                   2015 年第三季度报告




                                          目录
一、    重要提示 .................................................................. 3

二、    公司主要财务数据和股东变化 ................................................ 3

三、    重要事项 .................................................................. 6

四、    附录...................................................................... 9




                                             2 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                          2015 年第三季度报告




一、       重要提示


1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完

    整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人肖伟、主管会计工作负责人尹洪刚及会计机构负责人(会计主管人员)江锁成保

    证季度报告中财务报表的真实、准确、完整。

1.4 本公司第三季度报告未经审计。


二、       公司主要财务数据和股东变化


2.1 主要财务数据
                                                                     单位:元   币种:人民币
                                                                           本报告期末比上年
                                     本报告期末           上年度末
                                                                             度末增减(%)
总资产                            4,357,563,162.70     4,154,971,721.55                   4.88
归属于上市公司股东的净资产        2,736,565,909.50     2,499,041,342.48                   9.50
                                  年初至报告期末       上年初至上年报告     比上年同期增减
                                    (1-9 月)           期末(1-9 月)           (%)
经营活动产生的现金流量净额          309,300,331.25       268,893,648.02                 15.03
                                  年初至报告期末       上年初至上年报告     比上年同期增减
                                    (1-9 月)           期末(1-9 月)         (%)
营业收入                          2,136,168,515.51     1,883,954,928.08                 13.39
归属于上市公司股东的净利润          288,286,593.05       249,984,680.92                 15.32
归属于上市公司股东的扣除非
                                    278,510,175.70       244,258,618.16                 14.02
经常性损益的净利润
加权平均净资产收益率(%)                      10.98              12.58     减少 1.6 个百分点
基本每股收益(元/股)                          0.561              0.501                 11.98
稀释每股收益(元/股)                          0.561              0.501                 11.98

    公司主要会计数据和财务指标的说明

    公司 2014 年 9 月 30 日总股本为 498,776,029 股,故 2014 年 1-9 月指标按 498,776,029
股本计算;公司 2014 年 12 月 22 日完成非公开发行后总股本变为 513,707,601 股,故 2015
年 1-9 月指标按 513,707,601 股本计算。


                                             3 / 22
    江苏康缘药业股份有限公司 (股票代码:600557)                                     2015 年第三季度报告



非经常性损益项目和金额
√适用 □不适用
                                                                            单位:元 币种:人民币
                                                          本期金额        年初至报告期末
                       项目                                                                说明
                                                        (7-9 月)       金额(1-9 月)
非流动资产处置损益                                                           -150,819.62
计入当期损益的政府补助,但与公司正常经营
业务密切相关,符合国家政策规定、按照一定                2,769,807.21        7,043,007.76
标准定额或定量持续享受的政府补助除外
除上述各项之外的其他营业外收入和支出                    5,597,484.75        4,810,159.75
所得税影响额                                            -1,255,050.49      -1,875,576.38
少数股东权益影响额(税后)                                 -47,076.89             -50,354.16
                       合计                             7,065,164.58        9,776,417.35



2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                 单位:股
股东总数(户)                                                                                      29,917
                                            前十名股东持股情况
                                                           持有有限售      质押或冻结情况
         股东名称             期末持股数
                                              比例(%)      条件股份数                            股东性质
         (全称)                 量                                     股份状态      数量
                                                               量
                                                                                                境内非国有
江苏康缘集团有限责任公司      141,180,385       27.48      135,224,737      无
                                                                                                   法人

连云港康贝尔医疗器械有限                                                                        境内非国有
                               26,558,806        5.17                       无
公司                                                                                               法人

中国工商银行股份有限公司
-东方红中国优势灵活配置       16,594,839        3.23                      未知                    其他
混合型证券投资基金
中央汇金投资有限责任公司       15,233,400        2.97                      未知                    其他
萧伟                           14,169,699        2.76                       无                  境内自然人
汇添富基金-工商银行-汇
                                9,954,330        1.94        9,954,330     未知                    其他
添富-康缘资产管理计划
连云港本清企业管理咨询有
                                9,750,000        1.90                      未知                    其他
限公司
博时基金-农业银行-博时
                                4,532,900        0.88                      未知                    其他
中证金融资产管理计划
中欧基金-农业银行-中欧
                                4,532,900        0.88                      未知                    其他
中证金融资产管理计划
嘉实基金-农业银行-嘉实
                                4,532,900        0.88                      未知                    其他
中证金融资产管理计划


                                                  4 / 22
     江苏康缘药业股份有限公司 (股票代码:600557)                                  2015 年第三季度报告



银华基金-农业银行-银华
                                 4,532,900     0.88                   未知                       其他
中证金融资产管理计划
易方达基金-农业银行-易
                                 4,532,900     0.88                   未知                       其他
方达中证金融资产管理计划
大成基金-农业银行-大成
                                 4,532,900     0.88                   未知                       其他
中证金融资产管理计划
工银瑞信基金-农业银行-
工银瑞信中证金融资产管理         4,532,900     0.88                   未知                       其他
计划
                                     前十名无限售条件股东持股情况
                                                                               股份种类及数量
               股东名称                持有无限售条件流通股的数量
                                                                             种类               数量
连云港康贝尔医疗器械有限公司                             26,558,806    人民币普通股           26,558,806
中国工商银行股份有限公司-东方红
中国优势灵活配置混合型证券投资基                         16,594,839    人民币普通股           16,594,839

中央汇金投资有限责任公司                                 15,233,400    人民币普通股           15,233,400
萧伟                                                     14,169,699    人民币普通股           14,169,699
连云港本清企业管理咨询有限公司                            9,750,000    人民币普通股            9,750,000
江苏康缘集团有限责任公司                                  5,955,648    人民币普通股            5,955,648
博时基金-农业银行-博时中证金融
                                                          4,532,900    人民币普通股            4,532,900
资产管理计划
中欧基金-农业银行-中欧中证金融
                                                          4,532,900    人民币普通股            4,532,900
资产管理计划
嘉实基金-农业银行-嘉实中证金融
                                                          4,532,900    人民币普通股            4,532,900
资产管理计划
银华基金-农业银行-银华中证金融
                                                          4,532,900    人民币普通股            4,532,900
资产管理计划
易方达基金-农业银行-易方达中证
                                                          4,532,900    人民币普通股            4,532,900
金融资产管理计划
大成基金-农业银行-大成中证金融
                                                          4,532,900    人民币普通股            4,532,900
资产管理计划
工银瑞信基金-农业银行-工银瑞信
                                                          4,532,900    人民币普通股            4,532,900
中证金融资产管理计划
                                      前十大股东中,江苏康缘集团有限责任公司和萧伟先生存在关联关系,
                                      萧伟先生为江苏康缘集团有限责任公司第一大股东;汇添富基金-工商
                                      银行-汇添富-康缘资产管理计划为江苏康缘集团有限责任公司一致行
上述股东关联关系或一致行动的说明
                                      动人。公司未知其他股东之间、其他股东与前十名无限售条件股东之间
                                      是否存在关联关系或一致行动人关系;公司未知其他前十名无限售条件
                                      股东之间是否存在关联关系或一致行动人关系。




                                                5 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                          2015 年第三季度报告




三、    重要事项


3.1 公司主要会计报表项目、财务指标重大变动的情况及原因

√适用 □不适用
1、资产负债表项目
  报表项目          期末余额           期初余额         变动比例          变动原因
                                                                   主要系报告期内偿还贷款
  货币资金      264,686,777.09      553,542,219.35       -52.18%
                                                                   所致
                                                                   主要系报告期内数字化中
  在建工程      259,558,706.27      386,576,215.21       -32.86%   药提取精制工厂转入固定
                                                                   资产所致
                                                                   主要系报告期内公司偿还
  短期借款      363,000,001.00      695,000,000.00       -47.77%
                                                                   银行借款所致
                                                                   主要系报告期内公司采购
  应付票据       86,900,000.00       57,500,000.00        51.13%
                                                                   增加所致
                                                                   主要系报告系内公司采购
  应付账款      347,418,447.59      205,082,063.70        69.40%
                                                                   增加所致
                                                                   主要系报告期内公司销售
  应交税费       86,894,358.35       54,963,488.72        58.09%
                                                                   收入增长、利润增加所致
                                                                   主要系报告期内子公司支
  应付股利            24,375.00          186,769.39      -86.95%
                                                                   付现金股利所致
                                                                   主要系按照权责发生制、
 其他应付款     424,592,439.54      286,074,014.21        48.42%
                                                                   计提相关费用增加所致
 一年内到期                                                        主要系本报告期内部分长
 的非流动负      80,000,000.00       56,000,000.00        42.86%   期借款转入一年到到期非
     债                                                            流动负债所致
                                                                   主要系本报告期内部分长
  长期借款       55,000,000.00      125,000,000.00       -56.00%   期借款转入一年到到期非
                                                                   流动负债所致


2、利润表项目
  报表项目        本期金额           上期金额         变动比例           变动原因
                                                                 主要系报告期内公司贷款减
  财务费用      33,208,923.35      53,390,154.81       -37.80%
                                                                 少及银行同期利率下降所致
                                                                 主要系报告期内公司相较去
 营业外支出      1,354,373.48       2,767,549.48       -51.06%   年同期非流动资产处置减少
                                                                 所致




                                             6 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                        2015 年第三季度报告




3.2 重要事项进展情况及其影响和解决方案的分析说明

√适用 □不适用
    1、关于控股股东增持的情况说明

    2015 年 7 月 3 日,控股股东江苏康缘集团有限责任公司(以下简称“康缘集团”) 通过上
海证券交易所交易系统增持公司股份 640,000 股,占公司总股本的 0.12%。(详见 2015 年 7 月 6
日刊登于上海证券交易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告)。

    2015 年 7 月 8 日,康缘集团继续通过上海证券交易所交易系统增持公司股份 100,000 股,占
公司总股本的 0.02%。(详见 2015 年 7 月 9 日刊登于上海证券交易所网站 www.sse.com.cn、《中
国证券报》、《上海证券报》公告)。

    2、关于公司解聘高级管理人员的情况说明

    2015 年 8 月 14 日公司召开第五届董事会第十四次会议,审议并通过了《关于解聘高级管理
人员的议案》,因工作原因,免去胡长欣副总经理职务。(详见 2015 年 8 月 15 日刊登于上海证
券交易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告)。

    3、关于公司聘任财务总监的情况说明

    2015 年 8 月 14 日公司召开第五届董事会第十四次会议,审议并通过了《关于聘任财务总监
的议案》,聘任尹洪刚先生担任公司财务总监职务。(详见 2015 年 8 月 15 日刊登于上海证券交
易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告)。


3.3 公司及持股 5%以上的股东承诺事项履行情况

√适用 □不适用

                                                                  承诺时     是否有   是否及
承诺背景   承诺类型    承诺方                承诺内容             间及期     履行期   时严格
                                                                    限         限       履行
                                 公司 2007 年公开增发新股,公司
                                 控股股东江苏康缘集团有限责任
                                                                  承诺时
                                 公司在与本公司签署的《避免同
                                                                  间为
                       江苏康    业竞争股东协议书》中郑重承诺:
与再融资                                                          2007 年
           解决同业    缘集团    目前,公司所有业务,康缘集团
相关的承                                                          7 月 10      否       是
             竞争      有限责    及其控股和实际控制下的其他企
  诺                                                              日,本承
                       任公司    业均不涉及。康缘集团及其控股
                                                                  诺长期
                                 和实际控制下的其他企业与本公
                                                                  有效
                                 司及本公司控股、实际控制的企
                                 业间不存在同业竞争的情形。




                                             7 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                          2015 年第三季度报告



                                 公司 2007 年公开增发新股,江苏
                                 康缘集团有限责任公司承诺将尽
                                 量减少与本公司之间的关联交
                                 易。对于无法避免的任何业务往
                                 来或交易均应按照公平、公允和
                                                                   承诺时
                                 等价有偿的原则进行,交易价格
                                                                   间为
                       江苏康    应按市场公认的合理价格确定,
与再融资                                                           2007 年
           解决关联    缘集团    并按规定履行信息披露义务。康
相关的承                                                           7 月 10      否          是
             交易      有限责    缘集团及其控股和实际控制下的
  诺                                                               日,本承
                       任公司    其他企业与本公司及本公司控股
                                                                   诺长期
                                 和实际控制下的其他企业就相互
                                                                   有效
                                 间关联事务及交易所做出的任何
                                 约定及安排,均不妨碍对方为其
                                 自身利益、在市场同等竞争条件
                                 下与任何第三方进行业务往来或
                                 交易。
                                                                   2014 年
                       江苏康    公司 2014 年非公开发行股票,康
与再融资                                                           12 月 22
                       缘集团    缘集团承诺认购本次发行的股票
相关的承   股份限售                                                日-2017      是          是
                       有限责    自发行结束之日起 36 个月内不上
  诺                                                               年 12 月
                       任公司    市交易或转让。
                                                                   21 日
                       江苏康                                      2015 年
                                 康缘集团承诺在增持股份实施期
与增持相               缘集团                                      7月8日
             其他                间及法定期限内不减持所持有的                   是          是
关的承诺               有限责                                      -2016 年
                                 公司股份
                       任公司                                      1月7日



3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的

    警示及原因说明
□适用 √不适用
                                                      公司名称     江苏康缘药业股份有限公司
                                                      法定代表人              肖伟
                                                      日期            2015 年 10 月 29 日




                                             8 / 22
      江苏康缘药业股份有限公司 (股票代码:600557)                               2015 年第三季度报告




四、       附录


4.1     财务报表
                                           合并资产负债表
                                          2015 年 9 月 30 日
编制单位:江苏康缘药业股份有限公司

                                                      单位:元      币种:人民币   审计类型:未经审计
                    项目                                 期末余额                   年初余额
流动资产:
  货币资金                                                264,686,777.09             553,542,219.35
  结算备付金
  拆出资金
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据                                                539,749,111.72             485,195,446.65
  应收账款                                            1,161,628,318.51               942,260,117.97
  预付款项                                                 54,336,920.59               45,717,745.16
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  应收股利
  其他应收款                                               65,396,427.06               83,645,199.79
  买入返售金融资产
  存货                                                    182,212,034.80             144,615,901.04
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产
      流动资产合计                                    2,268,009,589.77             2,254,976,629.96
非流动资产:
  发放贷款及垫款
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资                                              3,978,696.86                3,976,346.70
  投资性房地产
  固定资产                                            1,424,084,752.98             1,106,803,231.16
  在建工程                                                259,558,706.27             386,576,215.21

                                                9 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                       2015 年第三季度报告



  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                            236,702,410.04      214,419,108.78
  开发支出                                            18,000,000.00         18,000,000.00
  商誉                                                58,988,858.14         58,988,858.14
  长期待摊费用                                          1,138,669.84         1,358,910.03
  递延所得税资产                                        7,326,353.47         7,525,437.08
  其他非流动资产                                      79,775,125.33       102,346,984.49
    非流动资产合计                                 2,089,553,572.93     1,899,995,091.59
         资产总计                                  4,357,563,162.70     4,154,971,721.55
流动负债:
  短期借款                                            363,000,001.00      695,000,000.00
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据                                            86,900,000.00         57,500,000.00
  应付账款                                            347,418,447.59      205,082,063.70
  预收款项                                            53,471,596.95         65,570,477.80
  卖出回购金融资产款
  应付手续费及佣金
  应付职工薪酬                                          3,660,060.47         3,197,857.64
  应交税费                                            86,894,358.35         54,963,488.72
  应付利息                                              1,300,785.08         1,503,319.52
  应付股利                                                24,375.00            186,769.39
  其他应付款                                          424,592,439.54      286,074,014.21
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  划分为持有待售的负债
  一年内到期的非流动负债                              80,000,000.00         56,000,000.00
  其他流动负债
    流动负债合计                                   1,447,262,063.98     1,425,077,990.98
非流动负债:
  长期借款                                            55,000,000.00       125,000,000.00
  应付债券
  其中:优先股
                                            10 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                          2015 年第三季度报告



           永续债
  长期应付款
  长期应付职工薪酬
  专项应付款                                            2,567,763.00            2,567,763.00
  预计负债
  递延收益                                             56,960,755.46           46,079,185.36
  递延所得税负债
  其他非流动负债
    非流动负债合计                                    114,528,518.46          173,646,948.36
         负债合计                                  1,561,790,582.44         1,598,724,939.34
所有者权益
  股本                                                513,707,601.00          513,707,601.00
  其他权益工具
  其中:优先股
           永续债
  资本公积                                            520,433,141.68          520,433,141.68
  减:库存股
  其他综合收益                                           -240,009.42             -848,743.49
  专项储备
  盈余公积                                            202,139,097.01          202,139,097.01
  一般风险准备
  未分配利润                                       1,500,526,079.23         1,263,610,246.28
  归属于母公司所有者权益合计                       2,736,565,909.50         2,499,041,342.48
  少数股东权益                                         59,206,670.76           57,205,439.73
    所有者权益合计                                 2,795,772,580.26         2,556,246,782.21
         负债和所有者权益总计                      4,357,563,162.70         4,154,971,721.55



法定代表人:肖伟          主管会计工作负责人:尹洪刚              会计机构负责人:江锁成




                                            11 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                            2015 年第三季度报告



                                      母公司资产负债表
                                      2015 年 9 月 30 日
编制单位:江苏康缘药业股份有限公司
                                                   单位:元     币种:人民币 审计类型:未经审计
                    项目                            期末余额                  年初余额
流动资产:
  货币资金                                            202,304,130.32           480,293,517.16
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据                                            480,515,125.96           378,394,069.88
  应收账款                                         1,003,727,905.33            799,883,464.78
  预付款项                                            49,024,223.34              37,305,823.45
  应收利息
  应收股利                                              4,759,107.34              4,759,107.34
  其他应收款                                          241,028,543.83             93,599,971.90
  存货                                                159,221,755.10           119,520,655.69
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产
    流动资产合计                                   2,140,580,791.22          1,913,756,610.20
非流动资产:
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资                                        189,532,779.53           191,712,542.37
  投资性房地产
  固定资产                                         1,196,727,834.14            870,835,909.87
  在建工程                                            187,528,844.20           349,099,137.47
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                                            166,553,611.96           141,103,501.13
  开发支出                                            18,000,000.00              18,000,000.00
  商誉
  长期待摊费用
  递延所得税资产                                        3,071,265.70              2,872,419.26
  其他非流动资产                                      67,419,604.75              59,140,757.99
    非流动资产合计                                 1,828,833,940.28          1,632,764,268.09
         资产总计                                  3,969,414,731.50          3,546,520,878.29
流动负债:

                                            12 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                       2015 年第三季度报告



  短期借款                                            323,000,001.00      450,000,000.00
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据                                            86,900,000.00         57,500,000.00
  应付账款                                            275,479,229.48      130,277,214.63
  预收款项                                            20,767,624.37         17,902,024.02
  应付职工薪酬                                          1,490,276.33         1,342,068.02
  应交税费                                            75,600,363.24         39,201,120.94
  应付利息                                               774,285.08            959,415.90
  应付股利
  其他应付款                                          316,471,930.53      182,991,384.19
  划分为持有待售的负债
  一年内到期的非流动负债                              70,000,000.00         40,000,000.00
  其他流动负债
    流动负债合计                                   1,170,483,710.03       920,173,227.70
非流动负债:
  长期借款                                            55,000,000.00       125,000,000.00
  应付债券
  其中:优先股
           永续债
  长期应付款
  长期应付职工薪酬
  专项应付款                                            2,567,763.00         2,567,763.00
  预计负债
  递延收益                                            33,732,702.08         26,077,709.29
  递延所得税负债
  其他非流动负债
    非流动负债合计                                    91,300,465.08       153,645,472.29
         负债合计                                  1,261,784,175.11     1,073,818,699.99
所有者权益:
  股本                                                513,707,601.00      513,707,601.00
  其他权益工具
  其中:优先股
           永续债
  资本公积                                            520,570,073.21      520,570,073.21
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                            200,331,936.45      200,331,936.45
  未分配利润                                       1,473,020,945.73     1,238,092,567.64
    所有者权益合计                                 2,707,630,556.39     2,472,702,178.30
                                            13 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                           2015 年第三季度报告



      负债和所有者权益总计                         3,969,414,731.50         3,546,520,878.29



法定代表人:肖伟            主管会计工作负责人:尹洪刚                会计机构负责人:江锁成




                                            14 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                               2015 年第三季度报告



                                          合并利润表
                                        2015 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                                   单位:元    币种:人民币     审计类型:未经审计
                                                             年初至报告期       上年年初至报告期
                      本期金额          上期金额
       项目                                                期末金额 (1-9       期末金额(1-9 月)
                      (7-9 月)        (7-9 月)
                                                                 月)
一、营业总收入     708,831,273.66     648,567,611.90      2,136,168,515.51      1,883,954,928.08
其中:营业收入     708,831,273.66     648,567,611.90      2,136,168,515.51       1,883,954,928.08
       利息收入
       已赚保费
      手续费及
佣金收入
二、营业总成本     600,829,003.67     538,123,007.73      1,805,691,257.61      1,584,561,688.20
其中:营业成本     183,083,560.48     163,200,935.59          553,300,541.94       487,734,796.77
       利息支出
      手续费及
佣金支出
       退保金
       赔付支出
净额
      提取保险
合同准备金净额
       保单红利
支出
       分保费用
       营业税金
                    11,229,514.74      10,273,220.94          34,951,559.70         29,741,698.60
及附加
       销售费用    317,038,445.36     283,872,348.01          913,264,704.35       787,931,897.70
       管理费用     77,775,887.62      60,317,969.01          269,563,515.02       224,534,607.41
       财务费用     10,951,887.34      19,932,563.37          33,208,923.35         53,390,154.81
       资产减值
                        749,708.13         525,970.81           1,402,013.25         1,228,532.91
损失
  加:公允价值变
动收益(损失以
“-”号填列)
       投资收益
(损失以“-”号      -606,579.76                               -604,229.60             -1,030.95
填列)
      其中:对联
营企业和合营企                 0.00                                2,350.16             -1,030.95
业的投资收益
       汇兑收益
                                            15 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                         2015 年第三季度报告



(损失以“-”号
填列)
三、营业利润(亏
                   107,395,690.23     110,444,604.17    329,873,028.30      299,392,208.93
损以“-”号填列)
  加:营业外收入     8,770,720.82       5,111,112.00     13,056,721.37        10,277,405.99
      其中:非流
动资产处置利得
  减:营业外支出        403,428.86         563,626.17     1,354,373.48         2,767,549.48
      其中:非流
动资产处置损失
四、利润总额(亏
损总额以“-”     115,762,982.19     114,992,090.00    341,575,376.19      306,902,065.44
号填列)
  减:所得税费用    17,177,449.45      25,116,812.05     51,287,552.11        54,704,899.97
五、净利润(净亏
损以“-”号填      98,585,532.74      89,875,277.95    290,287,824.08      252,197,165.47
列)
  归属于母公司
                    98,370,608.88      89,607,459.05    288,286,593.05      249,984,680.92
所有者的净利润
  少数股东损益          214,923.86         267,818.90     2,001,231.03         2,212,484.55
六、其他综合收益
                          1,456.25          -3,114.68           709.38            15,581.04
的税后净额
  归属母公司所
有者的其他综合            1,456.25          -3,114.68           709.38            15,581.04
收益的税后净额
    (一)以后不
能重分类进损益
的其他综合收益
    (二)以后将
重分类进损益的            1,456.25          -3,114.68           709.38            15,581.04
其他综合收益
      1.权益法
下在被投资单位
以后将重分类进
损益的其他综合
收益中享有的份

      2.可供出
售金融资产公允
价值变动损益
      3.持有至
到期投资重分类
为可供出售金融

                                            16 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                           2015 年第三季度报告



资产损益
       4.现金流
量套期损益的有
效部分
      5.外币财
                          1,456.25          -3,114.68             709.38            15,581.04
务报表折算差额
      6.其他
  归属于少数股
东的其他综合收
益的税后净额
七、综合收益总额    98,586,988.99      89,872,163.27      290,288,533.46      252,212,746.51
  归属于母公司
所有者的综合收      98,372,065.13      89,604,344.37      288,287,302.43      250,000,261.96
益总额
   归属于少数股
东的综合收益总          214,923.86         267,818.90       2,001,231.03         2,212,484.55

八、每股收益:
  (一)基本每股
                               0.19                0.18            0.561                 0.501
收益(元/股)
  (二)稀释每股
                               0.19                0.18            0.561                 0.501
收益(元/股)



法定代表人:肖伟          主管会计工作负责人:尹洪刚            会计机构负责人:江锁成




                                            17 / 22
      江苏康缘药业股份有限公司 (股票代码:600557)                             2015 年第三季度报告



                                            母公司利润表
                                           2015 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                                 单位:元 币种:人民币 审计类型:未经审计
                                                         年初至报告期期末 上年年初至报告期
                         本期金额          上期金额
        项目                                                    金额          期末金额
                         (7-9 月)        (7-9 月)
                                                             (1-9 月)       (1-9 月)
一、营业收入          601,584,547.81     544,628,834.59      1,816,886,255.63    1,596,345,047.76
     减:营业成本     157,232,668.36     143,052,924.28        479,337,325.71      425,166,032.32
         营业税金
                        9,088,686.11       8,379,425.66         29,436,335.98        25,079,285.86
及附加
         销售费用     250,809,236.66     215,924,465.64        727,491,713.26      615,925,355.45
         管理费用      67,789,199.77      49,682,381.84        232,457,707.71      191,864,916.59
         财务费用       8,688,393.18      15,711,499.98         21,834,311.04        40,821,599.60
         资产减值
                           864,323.10         591,870.33         1,325,642.91         1,185,221.20
损失
  加:公允价值变
动收益(损失以
“-”号填列)
       投资收益
(损失以“-”号         -469,084.07                              -466,733.91           794,469.05
填列)
      其中:对联
营企业和合营企                    0.00                               2,350.16            -1,030.95
业的投资收益
二、营业利润(亏
                   106,642,956.56        111,286,266.86       324,536,485.11       297,097,105.79
损以“-”号填列)
     加:营业外收入     8,615,720.81       4,366,300.00         12,888,921.36         7,579,654.00
      其中:非流
动资产处置利得
     减:营业外支出        399,309.47         562,410.84         1,349,004.09         2,751,961.84
      其中:非流
动资产处置损失
三、利润总额(亏
损总额以“-”号      114,859,367.90     115,090,156.02       336,076,402.38       301,924,797.95
填列)
      减:所得税费
                       17,099,256.72      25,680,591.97         49,777,264.19        53,616,785.64

四、净利润(净亏
                       97,760,111.18      89,409,564.05       286,299,138.19       248,308,012.31
损以“-”号填列)
五、其他综合收益
的税后净额
六、综合收益总额       97,760,111.18      89,409,564.05       286,299,138.19       248,308,012.31

                                               18 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                              2015 年第三季度报告




法定代表人:肖伟            主管会计工作负责人:尹洪刚               会计机构负责人:江锁成



                                       合并现金流量表
                                       2015 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                                   单位:元    币种:人民币   审计类型:未经审计
                 项目                       年初至报告期期末金额          上年年初至报告期期末
                                                  (1-9 月)                  金额(1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                      2,173,303,345.48            1,977,378,283.57
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当
期损益的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还                                                  0.00                360,000.00
  收到其他与经营活动有关的现金                        104,017,397.23               88,751,693.14
    经营活动现金流入小计                            2,277,320,742.71           2,066,489,976.71
  购买商品、接受劳务支付的现金                        348,979,177.00              350,389,944.57
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                      255,274,197.35              248,246,068.71
  支付的各项税费                                      367,231,319.68              343,573,796.15
  支付其他与经营活动有关的现金                        996,535,717.43              855,386,519.26
    经营活动现金流出小计                            1,968,020,411.46           1,797,596,328.69
      经营活动产生的现金流量净额                      309,300,331.25             268,893,648.02
二、投资活动产生的现金流量:
  收回投资收到的现金
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                              76,010.00             1,074,414.20
产收回的现金净额

                                            19 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                         2015 年第三季度报告



  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                   76,010.00           1,074,414.20
  购建固定资产、无形资产和其他长期资
                                                      280,712,561.70         279,623,427.21
产支付的现金
  投资支付的现金
  质押贷款净增加额
  取得子公司及其他营业单位支付的现
金净额
  支付其他与投资活动有关的现金                                135.54             177,530.70
    投资活动现金流出小计                              280,712,697.24         279,800,957.91
      投资活动产生的现金流量净额                   -280,636,687.24          -278,726,543.71
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  其中:子公司吸收少数股东投资收到的
现金
  取得借款收到的现金                               1,236,574,286.67          448,000,000.00
  发行债券收到的现金
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                           1,236,574,286.67          448,000,000.00
  偿还债务支付的现金                               1,474,162,128.08          439,000,000.00
  分配股利、利润或偿付利息支付的现金                   79,951,042.95          82,409,049.57
  其中:子公司支付给少数股东的股利、
利润
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                           1,554,113,171.03          521,409,049.57
      筹资活动产生的现金流量净额                   -317,538,884.36           -73,409,049.57
四、汇率变动对现金及现金等价物的影响                       19,798.09              20,429.08
五、现金及现金等价物净增加额                        -288,855,442.26          -83,221,516.18
  加:期初现金及现金等价物余额                        553,542,219.35         288,354,585.97
六、期末现金及现金等价物余额                          264,686,777.09         205,133,069.79



法定代表人:肖伟            主管会计工作负责人:尹洪刚             会计机构负责人:江锁成




                                            20 / 22
   江苏康缘药业股份有限公司 (股票代码:600557)                              2015 年第三季度报告



                                      母公司现金流量表
                                        2015 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                                   单位:元    币种:人民币   审计类型:未经审计
                 项目                       年初至报告期期末金额          上年年初至报告期期末
                                                  (1-9 月)                  金额(1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                      1,818,927,099.36           1,683,170,639.40
  收到的税费返还
  收到其他与经营活动有关的现金                         59,825,958.57               50,180,296.52
    经营活动现金流入小计                            1,878,753,057.93           1,733,350,935.92
  购买商品、接受劳务支付的现金                        296,586,412.88             300,027,929.65
  支付给职工以及为职工支付的现金                      203,620,576.31             188,509,211.69
  支付的各项税费                                      307,855,671.51             293,464,600.68
  支付其他与经营活动有关的现金                        848,188,175.96             657,302,973.37
    经营活动现金流出小计                            1,656,250,836.66           1,439,304,715.39
  经营活动产生的现金流量净额                          222,502,221.27             294,046,220.53
二、投资活动产生的现金流量:
  收回投资收到的现金                                    1,713,028.93
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期资
                                                              75,000.00             1,074,414.20
产收回的现金净额
  处置子公司及其他营业单位收到的现
金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                1,788,028.93                1,074,414.20
  购建固定资产、无形资产和其他长期资
                                                      265,919,528.29             255,282,196.34
产支付的现金
  投资支付的现金
  取得子公司及其他营业单位支付的现
金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                              265,919,528.29             255,282,196.34
      投资活动产生的现金流量净额                     -264,131,499.36            -254,207,782.14
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                  900,574,286.67             248,000,000.00
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                              900,574,286.67             248,000,000.00
  偿还债务支付的现金                                  948,162,128.08             268,000,000.00
  分配股利、利润或偿付利息支付的现金                   68,772,267.34               69,948,401.17
  支付其他与筹资活动有关的现金                        120,000,000.00                         0.00

                                            21 / 22
      江苏康缘药业股份有限公司 (股票代码:600557)                         2015 年第三季度报告



      筹资活动现金流出小计                            1,136,934,395.42          337,948,401.17
         筹资活动产生的现金流量净额                   -236,360,108.75           -89,948,401.17
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                           -277,989,386.84          -50,109,962.78
  加:期初现金及现金等价物余额                           480,293,517.16         177,603,677.73
六、期末现金及现金等价物余额                             202,304,130.32         127,493,714.95



法定代表人:肖伟             主管会计工作负责人:尹洪刚              会计机构负责人:江锁成




4.2     审计报告
□适用 √不适用




                                               22 / 22